Global Patent Index - EP 1988167 A3

EP 1988167 A3 2009-02-18 - Intracellular inhibiting peptides

Title (en)

Intracellular inhibiting peptides

Title (de)

Intrazellular hemmende Peptide

Title (fr)

Peptides inhibiteurs intracellulaires

Publication

EP 1988167 A3 (FR)

Application

EP 08102597 A

Priority

EP 05290363 A

Abstract (en)

[origin: EP1693458A1] A mitogen activated protein kinase inhibitor peptide which is covalently coupled to a fluorophore/with beta galactosidase or biotinyl enzymes, is new. A mitogen activated protein kinase inhibitor peptide which is covalently coupled to a fluorophore/with beta galactosidase or biotinyl enzymes. The enzymatic sequence is optionally surrounded by spacer. The export and localization sequence for intracellular signalling. The amino acids corresponding to docking domain of a mitogen activated protein kinase and allows the penetration of HIV-type I trans activating transcriptional activator protein in a cell. Independent claims are also included for: (1) a nucleic acid encoding the peptide; (2) a expression vector; and (3) a kit comprising the peptide and/or the expression vector.

IPC 8 full level (invention and additional information)

C12N 15/62 (2006.01); A61K 47/48 (2006.01)

CPC (invention and additional information)

C07K 14/4702 (2013.01); A61K 47/62 (2017.08); A61K 47/645 (2017.08); C07K 14/82 (2013.01); A61K 38/00 (2013.01); C07K 2319/09 (2013.01); C07K 2319/095 (2013.01); C07K 2319/10 (2013.01); C07K 2319/70 (2013.01)

Citation (search report)

  • [X] WO 2004068139 A2 20040812 - UNIV CALIFORNIA [US], et al
  • [X] WO 9852614 A2 19981126 - UNIV LELAND STANFORD JUNIOR [US], et al
  • [Y] WO 0239947 A2 20020523 - CENTRE NAT RECH SCIENT [FR], et al
  • [Y] WO 0062067 A1 20001019 - UNIV WASHINGTON [US]
  • [Y] WO 9404686 A1 19940303 - BIOGEN INC [US], et al
  • [Y] WO 03012068 A2 20030213 - CELLOMICS INC [US], et al
  • [X] WO 0190197 A1 20011129 - UNIV AUSTRALIAN [AU], et al
  • [X] BONNY C ET AL: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", DIABETES, vol. 50, no. 1, January 2001 (2001-01-01), pages 77 - 82, XP002172261, ISSN: 0012-1797
  • [X] WATANABE NOBUO ET AL: "Bio-effectiveness of Tat-catalase conjugate: a potential tool for the identification of H2O2-dependent cellular signal transduction pathways.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 28 MAR 2003, vol. 303, no. 1, 28 March 2003 (2003-03-28), pages 287 - 293, XP002366348, ISSN: 0006-291X
  • [X] HALL D J ET AL: "Transduction of a dominant-negative H-Ras into human eosinophils attenuates extracellular signal-regulated kinase activation and interleukin-5-mediated cell viability.", BLOOD, vol. 98, no. 7, 1 October 2001 (2001-10-01), pages 2014 - 2021, XP002366349, ISSN: 0006-4971
  • [X] MYOU SHIGEHARU ET AL: "Blockade of focal clustering and active conformation in beta 2-integrin-mediated adhesion of eosinophils to intercellular adhesion molecule-1 caused by transduction of HIV TAT-dominant negative Ras.", JOURNAL OF IMMUNOLOGY, vol. 169, no. 5, 1 September 2002 (2002-09-01), pages 2670 - 2676, XP002366350, ISSN: 0022-1767
  • [Y] FISCHER P M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIP OF TRUNCATED AND SUBSTITUTED ANALOGUES OF THE INTRACELLULAR DELIVERY VECTOR PENETRATIN", JOURNAL OF PEPTIDE RESEARCH, vol. 55, no. 2, February 2000 (2000-02-01), pages 163 - 172, XP000899124, ISSN: 1397-002X
  • [Y] MANN D A ET AL: "ENDOCYTOSIS AND TARGETING OF EXOGENOUS HIV-1 TAT PROTEIN", EMBO JOURNAL, vol. 10, no. 7, 1991, pages 1733 - 1739, XP001205687, ISSN: 0261-4189
  • [Y] NORI A ET AL: "Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells", BIOCONJUGATE CHEMISTRY, vol. 14, no. 1, 2003, pages 44 - 50, XP002347558, ISSN: 1043-1802
  • [Y] SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075
  • [Y] POUYSSEGUR J ET AL: "Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling", BIOCHEMICAL PHARMACOLOGY, vol. 64, no. 5-6, 1 September 2002 (2002-09-01), pages 755 - 763, XP002366351, ISSN: 0006-2952
  • [Y] BARDWELL A J ET AL: "Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity", BIOCHEMICAL JOURNAL, vol. 370, no. 3, 15 March 2003 (2003-03-15), pages 1077 - 1085, XP002366352, ISSN: 0264-6021
  • [X] KELEMEN, BRADLEY R. ET AL: "Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 177, no. 10, 26 December 2001 (2001-12-26), pages 8741 - 8748, XP002497901, ISSN: 0021-9258 & "SUPLEMETARY MATERIAL", 26 December 2001 (2001-12-26), XP002497902, Retrieved from the Internet <URL:http://www.jbc.org/cgi/content/full/277/10/8741/DC1> [retrieved on 20080917]SUPLEMETARY MATERIAL20011226http://www.jbc.org/cgi/content/full/277/10/8741/DC120080917
  • [Y] WENDER P A ET AL: "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 97, no. 24, 21 November 2000 (2000-11-21), pages 13003 - 13008, XP002347555, ISSN: 0027-8424
  • [Y] DEROSSI D ET AL: "TROJAN PEPTIDES: THE PENETRATIN SYSTEM FOR INTRACELLULAR DELIVERY", TRENDS IN CELL BIOLOGY, vol. 8, no. 2, 1 February 1998 (1998-02-01), pages 84 - 87, XP002940006, ISSN: 0962-8924
  • [X] GANJU R K ET AL: "Human immunodeficiency virus Tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells", JOURNAL OF VIROLOGY, vol. 72, no. 7, July 1998 (1998-07-01), pages 6131 - 6137, XP002497903, ISSN: 0022-538X

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

EPO simple patent family

EP 1693458 A1 20060823; CA 2597020 A1 20060824; CA 2597020 C 20160823; EP 1988167 A2 20081105; EP 1988167 A3 20090218; JP 2008529543 A 20080807; JP 5612248 B2 20141022; US 2009215680 A1 20090827; US 2016244493 A1 20160825; WO 2006087242 A2 20060824; WO 2006087242 A3 20071011

INPADOC legal status


2009-07-08 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20090612

2009-04-01 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20090219

2009-02-18 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A3

- Designated State(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

2008-11-12 [RTI1] TITLE (CORRECTION)

- Free text: INTRACELLULAR INHIBITING PEPTIDES

2008-11-05 [AC] DIVISIONAL APPLICATION (ART. 76) OF:

- Document: EP 1693458 P

2008-11-05 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR